NEW YORK, Dec. 4 – Affitech of Oslo and Axaron Bioscience of Heidelberg, Germany, said Tuesday that they had agreed to jointly develop and sel antibody drugs for neurological disorders. 

Axaron, formerly known as BASF-Lynx Bioscience, will use its transcription profiling technologies to identify targets that Affitech will then use in the development of antibodies. Both companies will support the effort to bring the antibodies through preclinical and clinical trials.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Microsoft co-founder Paul Allen also contributed to brain research, NPR reports.

The New York Times reports on the shifting interpretations of what some genetic variants mean over time.

In Cell this week: investigation of metastatic tumor evolution, more than 16,000 genetic variants introduced into the budding yeast model organism, and more.

MIT's Technology Review reports on Genentech's pursuit of personalized cancer vaccines.